Merrimack Pharmaceuticals Inc. buy marge
Summary
This prediction ended on 08.07.16 with a price of €51.41. The price of Merrimack Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.30%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -6,02 % | -4,60 % | 1,27 % | 48,62 % |
| iShares Nasdaq 100 | 0,51 % | 0,16 % | 14,57 % | 86,13 % |
| iShares Nikkei 225® | -7,16 % | -2,21 % | 28,11 % | 53,17 % |
| iShares S&P 500 | -0,26 % | -0,84 % | 10,20 % | 58,40 % |
Comments by marge for this prediction
In the thread Merrimack Pharmaceuticals Inc. diskutieren
FDA genehmigt: Die Behandlung von Patienten mit metastasiertem Bauchspeicheldrüsenkrebs!
A speculative pick of the bunch with a small biotech concern called Merrimack Pharmaceuticals, which is at under $7.00 a share, about half its levels earlier this summer. The stock has declined despite the fact the FDA approved Merrimack's main drug candidate MM-398 known by its brand name "Onivyde" , in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy in late October. Onivyde could eventually have $800 million in annual sales which is about equal to Merrimack's current market capitalization.
The company also has several promising compounds "MM-121, MM-141, MM-302" or "shots on goal" in early and mid-stage development as well. Merrimack recently raised $175 million to fund development of these drugs.
Four analysts have price targets on Merrimack in a relatively tight range of $13.00 to $15.00 a share.